Clinical evidence for psychedelic-assisted therapy is mounting.

This course presents a review of clinical research on psychedelic-assisted therapy, focusing on evidence for safety, tolerability, and effectiveness across several compounds. It includes a brief history of the field, summaries of findings by condition, and considerations for future research and adoption. The source material highlights evidence from more than 200 peer-reviewed studies and discusses outcomes reported for MDMA, psilocybin, ketamine, and other psychedelic compounds. It also outlines recommendations related to FDA approval, access, payer coverage, and public investment in research. The content is most relevant for clinicians, behavioral health professionals, researchers, and policy audiences seeking an overview of the current evidence base for psychedelic-assisted therapy.